FDA rubber-stamps Remdesivir for infants without evidence of safety, efficacy
The U.S. Food and Drug Administration approved the use of the antiviral therapy, remdesivir, to treat COVID-19 in infants 4 weeks and older, despite having no evidence the treatment is effective or even safe for young children.
•
